Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: HandsOn who wrote (176)	1/21/1999 5:31:00 PM
From: Mike McFarland	Respond to of 805

just chit chat I think we are going to need some patience tho...I see ctii went from 1.5 to 1.7 on the stem cell news the other day...then plopped right back down to 1 1/2...which I would imagine is some support level that traders come in (?) I really thought it would pop up on that news the other day...guess not. Here is a funny proposition--safety in microcap biotech! I checked all my watch lists this afternoon--I have a momentum biotech watch list, nearly everything was down...average of -4.5%. Then I check my value list...same thing, mostly down, an average loss of 3%. So I take a breath and check out the symbols I own, up 4%, ha ha, who would have thought...I guess on days when the market is trading down my stocks hold up okay because everybody who would sell has already gotten out;-) If that is the best rationale I can come up with for holding ctii, well then I must truly be attached to it...that's very bad, they call those people investors. --MM

To: HandsOn who wrote (176)	1/21/1999 6:51:00 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 805

Definately not chit chat: eurekalert.org Now, a study on mice by Angelo Vescovi, of NeuroSpheres Limited in Canada and the National Neurological Institute in Italy, and his colleagues suggests that stem cells don't have to come from embryos in order to generate specialized cells. "We went the other way around and used adult stem cells instead," said Vescovi. Hey dudes, time to make the thread a little more active...eh? corporate-ir.net In March 1994, the Company obtained an exclusive, worldwide license from NeuroSpheres, Ltd. for the commercial development and use of its proprietary neural stem cells for transplantation to treat human disease. In 1997, through the acquisition of StemCells, Inc., a company focused on the discovery and development of stem cells, CytoTherapeutics acquired additional intellectual property and licenses related to neural stem/progenitor cells. corporate-ir.net In March 1994, CytoTherapeutics announced that it had licensed a portfolio of patent applications from NeuroSpheres, Ltd. of Canada. CytoTherapeutics' neural stem patent estate currently consists of 7 issued U.S. patents and 13 pending U.S. patent applications related to stem/progenitor cells of the central and peripheral nervous systems. --Mike